Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Rheumatol Ther 2024;11(1):157–175 doi 10.1007/s40744-023-00624-3
Charles-Schoeman, et al. carried out a descriptive integrated analysis on patients with RA that were treated in the SELECT programme, with up to 6.5 years of exposure. They concluded that upadacitinib 15 mg QD had an acceptable safety profile, but long-term upadacitinib treatment was associated with dose-dependent laboratory abnormalities.
Six Phase 3 RCTs were included in this study: SELECT-EARLY, SELECT-NEXT, SELECT-MONOTHERAPY, SELECT-COMPARE, SELECT-BEYOND, and SELECT-CHOICE. Laboratory parameters included haemoglobin, neutrophils, lymphocytes, ALT, AST, CPK, creatinine, and lipids.
Keywords:
